Th1 inflammatory response (Th1)

The "Th1 inflammatory response" refers to a type of immune reaction orchestrated by Type 1 T helper cells (Th1 cells), which are a subset of CD4+ T lymphocytes. This is not a single molecular target but rather an immune pathway or functional state. Th1 responses are characterized by the secretion of cytokines such as interferon-gamma (IFNγ), interleukin 2 (IL2), and tumor necrosis factor-alpha (TNFα). These cytokines activate macrophages, enhance their ability to kill intracellular pathogens, stimulate cytotoxic T lymphocyte activity, and promote class switching in B cells to produce certain antibody types[1][2][3]. The Th1 pathway plays an essential role in defending against intracellular infections—such as those caused by viruses and some bacteria—and is also involved in anti-tumor immunity. Dysregulation or chronic activation of the Th1 response can contribute to autoimmune diseases and chronic inflammation[6][4]. Markers associated with Th1 cells include surface proteins like CCR5 and CXCR3; transcription factors such as T-bet; and secreted factors including IFNγ, IL2, TNFα[1]. The differentiation into the Th1 lineage is driven primarily by cytokines like IL12 produced by antigen-presenting cells during infection[5][4]. Because "Th1 inflammatory response" describes an immune process rather than a discrete protein or receptor target for drugs, it does not have canonical molecular identifiers or direct drug interactions. Instead, therapeutic strategies may aim to modulate this entire pathway through targeting its key cytokines or signaling molecules. In summary: "Th1 inflammatory response" is not itself a therapeutic target but rather describes an important immunological mechanism involving multiple cell types and mediators that play central roles in infection control, inflammation, autoimmunity, and cancer surveillance[3][6].

Other names

Th1 responseT helper 1 inflammatory responseType 1 T helper cell-mediated inflammation